Skip to Main Content

3,316

Views

1

CrossRef citations to date

0

Altmetric

Research Article

Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib

Ryan Jacobs1 Atrium Health Levine Cancer Institute (Hematology), Charlotte, NC28204, USAView further author information

,

Xiaoxiao Lu2 Janssen Scientific Affairs, LLC, Horsham, PA19044, USAView further author information

,

Bruno Emond3 Analysis Group, Inc., Montréal, QuébecH3B 0G7, CanadaCorrespondence[email protected]

https://orcid.org/0000-0002-0060-765X View further author information

,

Laura Morrison3 Analysis Group, Inc., Montréal, QuébecH3B 0G7, CanadaView further author information

,

Frederic Kinkead3 Analysis Group, Inc., Montréal, QuébecH3B 0G7, CanadaView further author information

,

Patrick Lefebvre3 Analysis Group, Inc., Montréal, QuébecH3B 0G7, CanadaView further author information

,

Marie-Hélène Lafeuille3 Analysis Group, Inc., Montréal, QuébecH3B 0G7, CanadaView further author information

,

Wasiulla Khan2 Janssen Scientific Affairs, LLC, Horsham, PA19044, USAView further author information

,

Linda H Wu2 Janssen Scientific Affairs, LLC, Horsham, PA19044, USAView further author information

,

Zaina P Qureshi2 Janssen Scientific Affairs, LLC, Horsham, PA19044, USAView further author information

&

Moshe Yair Levy4 Baylor Scott & White Research Institute, Dallas, TX75204, USAView further author information